ALUMIS INC.
ALMSNasdaq
$28.66
↑ +5.3%Jul 17 close · end-of-day
Price
1Y↑ +733.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$3.6B
Enterprise Value
$3.5B
P/E
—
P/S
426.6
P/B
6.3
EV/EBITDA
—
PEG
—
FCF Yield
-10.5%
Dividend Yield
—
Revenue (TTM)
$8.4M
Net Income (TTM)
-$237.4M
Free Cash Flow (TTM)
-$377.0M
Gross Margin
—
Operating Margin
-5364.0%
Net Margin
-2825.7%
ROE
-41.9%
ROIC
-70.8%
Debt / Equity
—
Net Cash
$63.9M
Return 1Y
+716.5%
Company profile
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.
- CEO
- Martin Babler
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- California
- Website
- www.alumis.com
Management & directors
- Pangali SanamChief Legal Officer
- Drappa JornChief Medical Officer
- Bradley Mark ChristopherChief Development Officer
- Goldstein DavidChief Scientific Officer
- Hardiman Roy C.Chief Business & Strategy Ofcr
- Richardson DerrickSVP, People and Culture
- Schroer John R.Chief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
ALMS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.7M↓ -90.0%
Diluted EPS-$0.74↓ -59.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | $24.1M |
| Gross profit | — | — | — |
| Operating income | -$158.2M | -$300.8M | -$453.8M |
| Net income | -$155.0M | -$294.2M | -$243.3M |
| Diluted EPS | -$72.08 | -$10.38 | -$2.86 |
| Operating cash flow | -$130.0M | -$255.1M | -$369.5M |
| Free cash flow | -$134.5M | -$256.8M | -$370.2M |
| Gross margin | — | — | — |
| Operating margin | — | — | -1886.9% |
| Net margin | — | — | -1011.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $17.4M | $2.7M | $2.1M | $1.9M | $1.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$56.1M | -$98.4M | -$98.6M | -$101.5M | -$140.5M | -$115.3M | -$96.4M | -$98.4M |
| Net income | -$56.5M | -$93.1M | -$94.8M | -$99.0M | $59.3M | -$110.8M | -$92.9M | -$93.1M |
| Diluted EPS | -$23.10 | -$1.73 | $35.48 | -$1.82 | $0.77 | -$1.06 | -$0.75 | -$0.74 |
| Operating cash flow | -$52.3M | -$83.8M | -$74.8M | -$80.4M | -$106.4M | -$110.9M | -$71.9M | -$87.1M |
| Free cash flow | -$52.7M | -$84.5M | -$75.1M | -$80.4M | -$107.0M | -$110.9M | -$71.9M | -$87.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | -583.9% | -5271.5% | -5580.4% | -4999.7% | -5652.4% |
| Net margin | — | — | — | -569.1% | 2225.1% | -5360.7% | -4817.6% | -5344.8% |
Company news
May 24, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-06 | Pangali Sanam· Chief Legal Officer | Sale | 5,000 | $28.00 | $140,000.00 | filing |
| 2026-07-06 | Pangali Sanam· Chief Legal Officer | Option exercise | 5,000 | $5.06 | $25,300.00 | filing |
| 2026-06-30 | AKKARAJU SRINIVAS | Award | 3,553 | $0.00 | $0.00 | filing |
| 2026-06-30 | Srivastava Sapna | Award | 3,553 | $0.00 | $0.00 | filing |
| 2026-06-30 | Machado Patrick | Award | 3,553 | $0.00 | $0.00 | filing |
| 2026-06-30 | TETRAULT LYNN A. | Award | 3,553 | $0.00 | $0.00 | filing |
| 2026-06-30 | Yao Zhengbin | Award | 3,553 | $0.00 | $0.00 | filing |
| 2026-05-22 | Drappa Jorn· Chief Medical Officer | Option exercise | 11,317 | $8.84 | $100,042.28 | filing |
| 2026-05-22 | Drappa Jorn· Chief Medical Officer | Option exercise | 15,535 | $5.06 | $78,607.10 | filing |
| 2026-04-01 | Tananbaum James B. | J | 1,123,337 | $0.00 | $0.00 | filing |
| 2026-04-01 | Tananbaum James B. | J | 1,123,337 | $0.00 | $0.00 | filing |
| 2026-04-01 | Tananbaum James B. | J | 680,486 | $0.00 | $0.00 | filing |
| 2026-04-01 | Foresite Capital Management VI LLC | J | 1,123,337 | $0.00 | $0.00 | filing |
| 2026-04-01 | Foresite Labs, LLC | J | 1,176,470 | $0.00 | $0.00 | filing |
| 2026-04-01 | Foresite Labs, LLC | J | 1,123,337 | $0.00 | $0.00 | filing |
| 2026-04-01 | Foresite Labs, LLC | J | 1,123,337 | $0.00 | $0.00 | filing |
| 2026-04-01 | Foresite Labs, LLC | J | 680,486 | $0.00 | $0.00 | filing |
| 2026-04-01 | Foresite Capital Management VI LLC | J | 1,176,470 | $0.00 | $0.00 | filing |
| 2026-04-01 | Foresite Capital Management VI LLC | J | 1,123,337 | $0.00 | $0.00 | filing |
| 2026-04-01 | Foresite Capital Management VI LLC | J | 680,486 | $0.00 | $0.00 | filing |
| 2026-04-01 | Tananbaum James B. | J | 1,176,470 | $0.00 | $0.00 | filing |
| 2026-01-09 | AKKARAJU SRINIVAS | Buy | 588,235 | $17.00 | $10.0M | filing |
| 2026-01-08 | Foresite Capital Management VI LLC | Buy | 294,117 | $17.00 | $5.0M | filing |
| 2026-01-08 | Foresite Labs, LLC | Buy | 294,117 | $17.00 | $5.0M | filing |
| 2026-01-08 | Tananbaum James B. | Buy | 294,117 | $17.00 | $5.0M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.